Predicting the impact of physiological and biochemical processes on oral drug bioavailability.
暂无分享,去创建一个
B Agoram | B. Agoram | W. Woltosz | M. Bolger | M B Bolger | W S Woltosz
[1] D. Greenblatt,et al. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole , 1999, Clinical pharmacology and therapeutics.
[2] Morton B. Brown,et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. , 1997, The Journal of clinical investigation.
[3] R. Oertel,et al. Intestinal secretion of intravenous talinolol is inhibited by luminal R‐verapamil , 1999, Clinical pharmacology and therapeutics.
[4] A. Boobis,et al. Human cytochromes P-450. , 1984, Xenobiotica; the fate of foreign compounds in biological systems.
[5] W. Higuchi,et al. Theoretical model studies of drug absorption and transport in the GI tract. 3. , 1972, Journal of pharmaceutical sciences.
[6] P J Sinko,et al. Development of predictive pharmacokinetic simulation models for drug discovery. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[7] S. Krähenbühl,et al. Interaction between grapefruit juice and midazolam in humans , 1995, Clinical pharmacology and therapeutics.
[8] Y. Tam. Individual Variation in First-Pass Metabolism , 1993, Clinical pharmacokinetics.
[9] D. Back,et al. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. , 1999, British journal of clinical pharmacology.
[10] K. Higaki,et al. Prediction of the Plasma Concentration Profiles of Orally Administered Drugs in Rats on the Basis of Gastrointestinal Transit Kinetics and Absorbability , 1997, The Journal of pharmacy and pharmacology.
[11] J. S. Wang,et al. Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole. , 1999, Pharmacology & toxicology.
[12] J. Kolars,et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. , 1994, Drug metabolism and disposition: the biological fate of chemicals.
[13] J. Leonard,et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir * , 1998, Clinical pharmacology and therapeutics.
[14] U. Kunzendorf,et al. Saturable First‐Pass Kinetics of Propranolol , 1989, Journal of clinical pharmacology.
[15] R. T. Coutts,et al. A computer simulation of the food effect: transient changes in hepatic blood flow and Michaelis-Menten parameters as mediators of hepatic first pass metabolism and bioavailability of propranolol. , 1990, Biopharmaceutics & drug disposition.
[16] D. Dunbar,et al. Characterization of human small intestinal cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[17] G L Amidon,et al. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. , 1996, Advanced drug delivery reviews.
[18] Y. Sugiyama,et al. Prediction of in vivo nonlinear first-pass hepatic metabolism of YM796 from in vitro metabolic data. , 1998, The Journal of pharmacology and experimental therapeutics.
[19] N. Holford,et al. Dose-dependent elimination of propranolol and its major metabolites in humans. , 1983, Journal of pharmaceutical sciences.
[20] T Lavé,et al. Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques. , 1999, Journal of medicinal chemistry.
[21] S. Krähenbühl,et al. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. , 1998, British journal of clinical pharmacology.
[22] M. E. Fitzsimmons,et al. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[23] R. Remmel,et al. First-pass disposition of (-)-6-aminocarbovir in rats. I. Prodrug activation may be limited by access to enzyme. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[24] H Lennernäs,et al. Membrane transport of drugs in different regions of the intestinal tract of the rat. , 1998, Journal of pharmaceutical sciences.
[25] J. Wagner. Propranolol: Pooled Michaelis‐Menten parameters and the effect of input rate on bioavailability , 1985, Clinical pharmacology and therapeutics.
[26] P. Gwilt,et al. The influence of diffusional barriers on presystemic gut elimination. , 1988, Drug metabolism and disposition: the biological fate of chemicals.
[27] B. Stoll,et al. A theory of molecular absorption from the small intestine , 2000 .
[28] P. Watkins,et al. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. , 1997, Advanced drug delivery reviews.
[29] S. Su,et al. Inhibition of the intestinal digoxin absorption and exsorption by quinidine. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[30] R. Hänsel,et al. Immunomodulating Properties of 5,20α(R)-Dihydroxy-6α,7α-epoxy-1-oxo-(5α)-witha-2,24-dienolide and Solasodine , 1982 .
[31] J. Monasterio,et al. Plasma concentrations and bioavailability of propranolol by oral, rectal, and intravenous administration in man. , 1986, Biopharmaceutics & drug disposition.
[32] H K Kroemer,et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.
[33] J. Kanto,et al. Midazolam: The First Water‐soluble Benzodiazepine; Pharmacology, Pharmacokinetics and Efficacy in Insomnia and Anesthesia , 1985, Pharmacotherapy.
[34] W. H. Barr,et al. Intestinal drug absorption and metabolism. I. Comparison of methods and models to study physiological factors of in vitro and in vivo intestinal absorption. , 1970, Journal of pharmaceutical sciences.
[35] Lawrence X. Yu,et al. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans , 1996 .
[36] R. Fontana,et al. Molecular and physical mechanisms of first-pass extraction. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[37] J. Silverman,et al. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. , 1998, The Journal of pharmacology and experimental therapeutics.
[38] Y. Sugiyama,et al. Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. , 1997, The Journal of pharmacology and experimental therapeutics.
[39] M. Gray,et al. Models of hepatic drug elimination. , 1992, Drug metabolism reviews.
[40] P Langguth,et al. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. , 1999, Journal of pharmaceutical sciences.
[41] R. Weaver,et al. Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[42] L. Benet,et al. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.
[43] G L Amidon,et al. A compartmental absorption and transit model for estimating oral drug absorption. , 1999, International journal of pharmaceutics.
[44] R. Brauer. Liver circulation and function. , 1963, Physiological reviews.
[45] B. Hoener,et al. Predicting the hepatic clearance of xenobiotics in humans from in vitro data , 1994, Biopharmaceutics & drug disposition.
[46] D. Shen,et al. First‐pass metabolism of midazolam by the human intestine , 1996, Clinical pharmacology and therapeutics.
[47] W. Higuchi,et al. Theoretical model studies of drug absorption and transport in the gastrointestinal tract.i. , 1970, Journal of pharmaceutical sciences.
[48] J. Kolars,et al. CYP3A gene expression in human gut epithelium. , 1994, Pharmacogenetics.
[49] W. Jusko,et al. Michaelis-Menten metabolite formation kinetics: equations relating area under the curve and metabolite recovery to the administered dose. , 1990, Journal of pharmaceutical sciences.
[50] J B Houston,et al. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. , 1997, Drug metabolism reviews.
[51] T. Walle,et al. Food effects on propranolol systemic and oral clearance: Support for a blood flow hypothesis , 1986, Clinical pharmacology and therapy.
[52] J. Aronson. Clinical Pharmacokinetics of Digoxin 1980 , 1980, Clinical pharmacokinetics.
[53] T. Lavé,et al. Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations. , 1995, Journal of pharmaceutical sciences.
[54] G. Amidon,et al. Physicochemical model for dose-dependent drug absorption. , 1984, Journal of pharmaceutical sciences.
[55] B. Brodie,et al. On the mechanism of intestinal absorption of drugs. , 1959, The Journal of pharmacology and experimental therapeutics.
[56] L. Benet,et al. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. , 1998, Biochemical pharmacology.
[57] K. Arimori,et al. The intestinal dialysis of intravenously administered phenytoin by oral activated charcoal in rats. , 1987, Journal of pharmacobio-dynamics.
[58] Y. Sugiyama,et al. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[59] T Lavé,et al. Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo Correlations , 1999, Clinical pharmacokinetics.
[60] P. Swaan,et al. Mapping the binding site of the small intestinal peptide carrier (PepT1) using comparative molecular field analysis. , 1998, Receptors & channels.
[61] G L Amidon,et al. Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[62] M. H. Jacobs. SOME ASPECTS OF CELL PERMEABILITY TO WEAK ELECTROLYTES , 1940 .
[63] S. Pond,et al. First-Pass Elimination Basic Concepts and Clinical Consequences , 1984, Clinical pharmacokinetics.
[64] W. Higuchi,et al. Quantitative interpretation of in vivo buccal absorption of n-alkanoic acids by the physical model approach. , 1971, Journal of pharmaceutical sciences.
[65] D. Shen,et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.
[66] J. Meier. Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents. , 1982, American heart journal.
[67] J. Lipsky,et al. Drug-grapefruit juice interactions. , 2000, Mayo Clinic proceedings.
[68] Thomas J. Raub,et al. Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. , 1995, Journal of pharmaceutical sciences.
[69] D. Greenblatt,et al. Bioavailability of Drugs: The Digoxin Dilemma , 1976, Clinical pharmacokinetics.
[70] P. du Souich,et al. First-pass metabolism of lidocaine in the anesthetized rabbit. Contribution of the small intestine. , 1996, Drug Metabolism And Disposition.
[71] J. Voigt,et al. Localization, distribution, and induction of xenobiotic-metabolizing enzymes and aryl hydrocarbon hydroxylase activity within lung. , 1990, Pharmacology & therapeutics.
[72] D. Greenblatt,et al. Midazolam Hydroxylation by Human Liver Microsomes In Vitro: Inhibition by Fluoxetine, Norfluoxetine, and by Azole Antifungal Agents , 1996, Journal of clinical pharmacology.
[73] Shand Dg. Pharmacokinetics of propranolol: a review. , 1976 .
[74] E. Iisalo. Clinical Pharmacokinetics of Digoxin , 1977, Clinical pharmacokinetics.
[75] William H. Press,et al. The Art of Scientific Computing Second Edition , 1998 .
[76] Morton B. Brown,et al. Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine , 1997, Clinical pharmacology and therapeutics.
[77] T Ishizaki,et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.
[78] K. Pang,et al. A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[79] N. Baber,et al. Bioavailability of sustained release propranolol formulations. , 1981, Biopharmaceutics & drug disposition.